Erratum: Clinical Research Trends of Botulinum Toxin Injection at Acupoints: A Scoping Review

Results : Eighty-three records were identified, of which 11 studies met inclusion criteria.Five were randomized controlled trials, with the remainder being prospective single-arm studies, non-randomized comparative studies, case series, or case reports.Indications included migraine or vestibular migraine (n=5), musculoskeletal pain (n=3), spasticity (n=1), and blepharospasm/hemifacial spasm (n=2), plus one status migrainosus case.Frequently used acupoints included EX-HN3, EX-HN5, GV20, GB8, GB20, and BL10; musculoskeletal studies also used Ashi (tender) points.Reported outcomes generally favored acupoint-based BoNT in reducing pain, attack frequency, or spasticity.Adverse events were reported in 9 studies and were mostly mild and transient.